New drug combo aims to shrink ovarian tumors before surgery, no chemo needed
NCT ID NCT07033819
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two oral drugs, fuzuloparib and apatinib, given before surgery to women with a specific genetic type (HRD-positive) of advanced ovarian cancer. The goal is to shrink tumors enough for complete surgical removal, potentially improving outcomes and avoiding chemotherapy. The study will enroll 48 participants and measure how many achieve successful tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fuzuloparib and apatinib (oral drugs)
What this could lead to
If successful, this drug combination could shrink tumors before surgery, making complete removal more likely and potentially improving survival for women with a specific type of advanced ovarian cancer.
What could go wrong
This is a small, early-phase trial with only 48 participants, so results may not apply broadly. Side effects from the drugs could occur, and the approach may not work better than standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••